Gilbert, A, Drinkwater, K, McParland, L et al. (7 more authors) (2020) UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. European Journal of Cancer, 128. pp. 7-16. ISSN 0959-8049
Abstract
Background
Concurrent chemoradiotherapy is the standard treatment for anal cancer. Following national UK implementation of intensity-modulated radiotherapy (IMRT), this prospective, national cohort evaluates the one-year oncological outcomes and patient-reported toxicity outcomes (PRO) after treatment.
Materials and methods
A national cohort of UK cancer centers implementing IMRT was carried out between February to July 2015. Cancer centers provided data on oncological outcomes, including survival, and disease and colostomy status at one-year. EORTC-QLQ core (C30) and colorectal (CR29) questionnaires were completed at baseline and one-year followup. The PRO scores at baseline and one year were compared.
Results
40 UK Cancer Centers returned data with a total of 187 patients included in the analysis. 92% received mitomycin with 5-fluorouracil or capecitabine. One-year overall survival was 94%; 84% were disease-free and 86% colostomy-free at one-year followup. At one year, PRO results found significant improvements in buttock pain, blood and mucus in stools, pain, constipation, appetite loss, and health anxiety compared to baseline. No significant deteriorations were reported in diarrhea, bowel frequency, and flatulence. Urinary symptom scores were low at one year. Moderate impotence symptoms at baseline remained at one year, and a moderate deterioration in dyspareunia reported.
Conclusions
With national anal cancer IMRT implementation, at this early pre-defined time point, one-year oncological outcomes were reassuring and resulted in good disease-related symptom control. one-year symptomatic complications following CRT for anal cancer using IMRT techniques appear to be relatively mild. These PRO results provide a basis to benchmark future studies.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2020, Elsevier Ltd. All rights reserved. This is an author produced version of an article published in European Journal of Cancer. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Anal cancer; Patient-reported outcomes; Intensity-modulated radiotherapy |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
Funding Information: | Funder Grant number Academy of Medical Sciences N/A Cancer Research UK A28301 |
Depositing User: | Symplectic Publications |
Date Deposited: | 21 Feb 2020 16:20 |
Last Modified: | 05 Mar 2021 01:38 |
Status: | Published |
Publisher: | Elsevier |
Identification Number: | 10.1016/j.ejca.2019.12.022 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:157392 |
Downloads
Filename: RCR Anal IMRT Manuscript Resubmission Clean.pdf
Licence: CC-BY-NC-ND 4.0
Filename: Tables RCR Anal IMRT for resubmission.pdf
Licence: CC-BY-NC-ND 4.0
Filename: Supplementary data for revised manuscript.pdf
Licence: CC-BY-NC-ND 4.0